4.8 Article

Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis

Journal

GUT
Volume 63, Issue 2, Pages 236-243

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/gutjnl-2013-304531

Keywords

-

Funding

  1. USA National Institutes of Health, National Cancer Institute
  2. Oak Ridge Associated Universities' Research Associates/Specialists Program
  3. Japanese Ministry of Education, Culture, Sports, Science and Technology [17015018, 221S0001]
  4. JSPS A3 Foresight Program
  5. Spanish Ministry of Health [exp. PI070130, PI081420]
  6. European Commission [QLG1-CT-2001-01049]
  7. Spanish Ministry of Health network RTICCC [ISCIII RD06/0020/0091]
  8. Chilean National Fund for Scientific and Technological Development, Fondecyt [. 1111014]
  9. Research Fund for the Control of Infectious Diseases, RFCID, Hong Kong [11100022]
  10. National Research Foundation of Korea [2012R1A1A3015504] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

Background and objective About 9% of gastric carcinomas have Epstein-Barr virus (EBV) in the tumour cells, but it is unclear whether viral presence influences clinical progression. We therefore examined a large multicentre case series for the association of tumour EBV status with survival after gastric cancer diagnosis, accounting for surgical stage and other prognostic factors. Methods We combined individual-level data on 4599 gastric cancer patients diagnosed between 1976 and 2010 from 13 studies in Asia (n=8), Europe (n=3), and Latin America (n=2). EBV positivity of tumours was assessed by in situ hybridisation. Mortality HRs for EBV positivity were estimated by Cox regression models stratified by study, adjusted for distributions of sex (71% male), age (mean 58years), stage (52% tumour-node-metastasis stages III or IV), tumour histology (49% poorly differentiated, 57% Lauren intestinal-type), anatomic subsite (70% non-cardia) and year of diagnosis. Variations by study and continent were assessed using study-specific HRs for EBV positivity. Results During median 3.0years follow-up, 49% of patients died. Stage was strongly predictive of mortality, with unadjusted HRs (vs stage I) of 3.1 for stage II, 8.1 for stage III and 13.2 for stage IV. Tumour EBV positivity was 8.2% overall and inversely associated with stage (adjusted OR: 0.79 per unit change). Adjusted for stage and other confounders, EBV positivity was associated with lower mortality (HR, 0.72; 95% CI 0.61 to 0.86), with low heterogeneity among the study populations (p=0.2). The association did not significantly vary across patient or tumour characteristics. There was no significant variation among the three continent-specific HRs (p=0.4). Conclusions Our findings suggest that tumour EBV positivity is an additional prognostic indicator in gastric cancer. Further studies are warranted to identify the mechanisms underlying this protective association.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available